Form 4: Macrogenics Director Reports Stock Transactions

Macrogenics Director William K. Heiden reported transactions involving restricted stock units and stock options.

Summary

• William K. Heiden, a Director at Macrogenics Inc., reported several transactions related to his beneficial ownership of company stock.
• On May 18, 2026, 3,750 restricted stock units (RSUs) vested, and these were disposed of, resulting in a net ownership of 114,750 shares of common stock.
• On May 19, 2026, an additional 3,750 RSUs were acquired, which are set to vest one year after the grant date or the day prior to the next annual meeting, whichever is earlier.
• Also on May 19, 2026, a stock option to purchase 22,000 shares of common stock at an exercise price of $4.52 was acquired. This option vests and becomes exercisable in monthly increments starting one month from the grant date, with full vesting over 12 months.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily details routine insider transactions related to compensation and equity awards rather than significant strategic shifts or financial performance indicators.

Positives

• Director William K. Heiden's acquisition of additional RSUs and stock options indicates continued alignment with the company's performance and potential future growth.
• The vesting of RSUs on May 18, 2026, suggests that performance or time-based conditions have been met.

Negatives

• The disposal of 3,750 vested RSUs on May 18, 2026, could be interpreted as a sale of shares, though the filing does not explicitly state a sale.
• The filing does not provide details on the reason for the disposal of the vested RSUs.

Risks

• The value of the acquired stock options is subject to market fluctuations and the company's future stock performance.
• The vesting schedule for the new RSUs and stock options means that the full benefit is realized over time, contingent on continued employment or service.

Future Outlook

The stock option acquired on May 19, 2026, will vest and become exercisable in monthly increments starting one month from the grant date, with full vesting over 12 months. The newly acquired RSUs will vest one year after the grant date or the day prior to the next annual meeting, if earlier.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions, providing transparency into the holdings and activities of company directors and officers. These transactions can offer insights into management's confidence in the company's prospects.

Stakeholder Impact

• Shareholders gain transparency into director compensation and equity holdings.
• Employees may view these transactions as indicators of management's commitment and confidence in the company.

Next Steps

• The stock option will vest and become exercisable in monthly increments starting one month from the grant date.
• The newly acquired RSUs will vest one year after the grant date or the day prior to the next annual meeting, if earlier.

Key Dates

Keywords

Macrogenics Inc., MGNX, Form 4, Insider Trading, Stock Options, Restricted Stock Units, Beneficial Ownership, William K. Heiden, SEC Filing